

NOVOGEN LIMITED

30 JUNE 2013

**PRELIMINARY FINAL REPORT
APPENDIX 4E**

ASX Code: NRT



DIRECTORS' REVIEW OF THE PRELIMINARY FINAL REPORT**OPERATING AND FINANCIAL REVIEW****Review of financial condition**

The consolidated entity produced a net loss after taxation, attributable to the owners of Novogen Limited of \$1,030,852 (2012: profit of \$1,309,071).

Net Tangible Assets of the consolidated entity as at 30 June 2013 were \$1,510,480 (2012: \$5,113,071), or 1.09 cents per share (2012: 4.93 cents).

Review of principal business

Since its inception in 1994, the principal business of Novogen has been pharmaceutical drug development. By the beginning of the current reporting period (1 July 2012), Novogen had ceased this or any other business. The previous Novogen Board had divested the company of all intellectual property in this area and of any resources and personnel relevant to R&D. The pharmaceutical drug development business was restored on 5 December 2012 with the acquisition of private biotechnology company, Triaxial Pharmaceuticals Pty Ltd.

That acquisition brought to the company a novel drug design and manufacture technology platform focused on the development of anti-cancer drugs known as super-benzopyrans and which attack the bio-energetic mechanism within cancer cells.

The company has identified a lead drug candidate, Trilexium, that currently is undergoing pre-clinical studies with a view to being in the clinic in the first half of 2014. Work is proceeding to identify a range of related drugs with similar principal action but directed at different cancer genotypes.

The stated goal of the company is to provide the technology and drugs capable of covering a wide range of different cancer cell genotypes and phenotypes that will permit the optimisation of chemotherapy on an individual basis. The company's R&D efforts are directed towards this goal.

Matters subsequent to the end of the financial year

On 4 July 2013, the company announced that it had put in place a funding arrangement with a sophisticated US-based institutional investor, providing it with up to \$5 million of working capital over the next three years.

There were no other significant matters subsequent to the end of the financial year.



Dr Graham Kelly

Chairman

APPENDIX 4E

PRELIMINARY FINAL REPORT

1. Company details

Name of entity:	Novogen Limited
ABN:	37 063 259 754
Reporting period:	Year ended 30 June 2013
Previous corresponding period:	Year ended 30 June 2012

2. Results for announcement to the market

Revenues from ordinary activities	down 23.1%	to	\$ 1,111,936
Loss from ordinary activities after tax attributable to the owners of Novogen Limited	down 178.7%	to	\$(1,030,852)
Loss for the period attributable to the owners of Novogen Limited	down 178.7%	to	\$(1,030,852)

Dividends

On 27 November 2012, a dividend of \$24,774,709 was paid via an in-specie distribution of shares in MEI Pharma, Inc. representing 23.87 cents per ordinary share.

Comments

The loss for the consolidated entity after providing for income tax and non-controlling interest amounted to \$1,030,852 (30 June 2012: profit of \$1,309,071).

For detailed commentary on results for the year, refer to operating and financial review preceding this Appendix 4E.

3. Net tangible assets

	Reporting period	Previous corresponding period
Net tangible assets per ordinary security	1.09 cents	4.93 cents

4. Control gained over entities

Name of entities (or group of entities)	Triaxial Pharmaceuticals Pty Ltd
---	----------------------------------

Date control gained	5 December 2012
---------------------	-----------------

Contribution of such entities to the reporting entity's profit/(loss) from ordinary activities before income tax during the period (where material)	\$(29,665)
---	------------

Profit/(loss) from ordinary activities before income tax of the controlled entity (or group of entities) for the whole of the previous corresponding period (where material)	\$ -
--	------

Novogen Limited
Preliminary final report

5. Loss of control over entities

Name of entities (or group of entities)	MEI Pharma, Inc. and its subsidiary MEI Pharma Pty Limited, were disposed of by way of an in-specie distribution to Novogen Limited's shareholders.
Date control lost	27 November 2012
Contribution of such entities to the reporting entity's profit/(loss) from ordinary activities after income tax during the period (where material)	\$(16,741,853)
Profit/(loss) from ordinary activities after income tax of the controlled entity (or group of entities) whilst controlled during the whole of the previous corresponding period (where material)	\$(8,259,693)

6. Dividends

Current period

On 27 November 2012, a dividend of \$24,774,709 was paid via an in-specie distribution of shares in MEI Pharma, Inc. representing 23.87 cents per ordinary share.

Previous corresponding period

There were no dividends paid, recommended or declared during the previous financial period.

7. Dividend reinvestment plans

The following dividend or distribution plans are in operation:

Not applicable.

The last date(s) for receipt of election notices for the dividend or distribution plans: Not applicable.

8. Details of associates and joint venture entities

Name of associate / joint venture	Reporting entity's percentage holding		Contribution to profit/(loss) (where material)	
	Current period	Previous corresponding period	Current period	Previous corresponding period
Not applicable.				
<i>Group's aggregate share of associates and joint venture entities' profit/(loss) (where material)</i>				
Profit/(loss) from ordinary activities before income tax			\$ -	\$ -
Income tax on operating activities			\$ -	\$ -

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

Not applicable.

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The accounts are currently in the process of being audited and an unqualified opinion is expected to be issued, with an emphasis of matter with respect to going concern.

11. Attachments

Details of attachments (if any):

The Preliminary Final Report of Novogen Limited for the year ended 30 June 2013 is attached.

12. Signed

Signed: _____



Date: 30 August 2013

Prof. Graham Kelly
Chairman
Sydney